Technical Analysis for BPMC - Blueprint Medicines Corporation
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New 52 Week Closing High | Bullish | -0.99% | |
Upper Bollinger Band Walk | Strength | -0.99% | |
Outside Day | Range Expansion | -0.99% | |
Wide Bands | Range Expansion | -0.99% | |
Above Upper BB | Strength | -0.99% | |
Overbought Stochastic | Strength | -0.99% | |
Upper Bollinger Band Touch | Strength | -0.99% | |
Slingshot Bullish | Bullish Swing Setup | 1.15% | |
Calm After Storm | Range Contraction | 1.15% | |
Upper Bollinger Band Walk | Strength | 1.15% |
Alert | Time |
---|---|
60 Minute Opening Range Breakout | about 2 hours ago |
Down 1% | about 3 hours ago |
Fell Below Upper Bollinger Band | about 3 hours ago |
Slingshot Bullish Entry | 1 day ago |
Rose Above Previous Day's High | 1 day ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/02/2024
Blueprint Medicines Corporation Description
Blueprint Medicines Corporation, a biopharmaceutical company, focuses on the development of the highly selective kinase inhibitors for genomically defined cancer subsets. The company's lead drug candidates include BLU-285, which targets KIT Exon 17 and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants for patients with systemic mastocytosis, a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor, as well as targets the KIT D816V mutation; and BLU-554, an orally available, potent, selective, and irreversible inhibitor, which targets FGFR4. It is also developing a drug candidate to target RET, a receptor tyrosine kinase that can becomes abnormally activated when a portion of the gene that encodes RET is joined to part of another gene; and RET resistant mutants that would arise from treatment with first generation therapies, as well as a program that targets rare genetic diseases. The company has a research, development, and commercialization agreement with Alexion Pharma Holding to research, develop, and commercialize drug candidates for an undisclosed activated kinase target, which is the cause of a rare genetic disease. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is based in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Gastrointestinal Cell Biology Protein Kinase Inhibitor Tyrosine Kinase Receptors Tyrosine Kinase Genetic Diseases Cell Signaling Fibroblast Growth Factor Receptor Rare Genetic Disease Rare Genetic Diseases Mastocytosis Systemic Mastocytosis Gastrointestinal Stromal Tumor Mast Cell Receptor Tyrosine Kinase
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 110.93 |
52 Week Low | 43.89 |
Average Volume | 772,725 |
200-Day Moving Average | 71.86 |
50-Day Moving Average | 92.27 |
20-Day Moving Average | 93.63 |
10-Day Moving Average | 98.43 |
Average True Range | 4.97 |
RSI (14) | 72.53 |
ADX | 19.37 |
+DI | 32.85 |
-DI | 15.48 |
Chandelier Exit (Long, 3 ATRs) | 96.02 |
Chandelier Exit (Short, 3 ATRs) | 99.24 |
Upper Bollinger Bands | 108.12 |
Lower Bollinger Band | 79.14 |
Percent B (%b) | 1.01 |
BandWidth | 30.95 |
MACD Line | 4.11 |
MACD Signal Line | 2.11 |
MACD Histogram | 2.0015 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 117.70 | ||||
Resistance 3 (R3) | 116.97 | 113.19 | 116.18 | ||
Resistance 2 (R2) | 113.19 | 110.86 | 113.56 | 115.67 | |
Resistance 1 (R1) | 110.87 | 109.42 | 112.03 | 111.60 | 115.16 |
Pivot Point | 107.09 | 107.09 | 107.67 | 107.46 | 107.09 |
Support 1 (S1) | 104.77 | 104.76 | 105.93 | 105.50 | 101.94 |
Support 2 (S2) | 100.99 | 103.32 | 101.36 | 101.43 | |
Support 3 (S3) | 98.67 | 100.99 | 100.93 | ||
Support 4 (S4) | 99.40 |